SciBase Holding Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

SciBase Holding wird ein Gewinn- und Umsatzwachstum von 51.9% bzw. 40% pro Jahr prognostiziert, während der Gewinn pro Aktie um 64.6% pro Jahr wachsen soll.

Wichtige Informationen

51.9%

Wachstumsrate der Gewinne

64.6%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	25.1%
Wachstumsrate der Einnahmen	40.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OM:SCIB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	79	-12	-17	-9	2
12/31/2025	49	-34	-36	-32	2
12/31/2024	30	-49	-55	-51	2
3/31/2024	24	-56	-62	-61	N/A
12/31/2023	23	-56	-52	-52	N/A
9/30/2023	22	-51	-50	-49	N/A
6/30/2023	20	-46	-42	-41	N/A
3/31/2023	19	-44	-38	-38	N/A
12/31/2022	18	-43	-45	-44	N/A
9/30/2022	17	-42	-42	-42	N/A
6/30/2022	15	-41	-41	-41	N/A
3/31/2022	13	-43	-41	-41	N/A
12/31/2021	12	-42	-40	-40	N/A
9/30/2021	11	-38	-38	-38	N/A
6/30/2021	10	-36	-36	-36	N/A
3/31/2021	10	-34	-36	-35	N/A
12/31/2020	10	-35	-34	-34	N/A
9/30/2020	9	-35	-33	-32	N/A
6/30/2020	9	-38	-36	-36	N/A
3/31/2020	9	-40	-38	-37	N/A
12/31/2019	9	-40	-39	-38	N/A
9/30/2019	9	-41	-40	-39	N/A
6/30/2019	8	-44	-38	-37	N/A
3/31/2019	7	-43	-37	-37	N/A
12/31/2018	7	-44	-38	-37	N/A
9/30/2018	7	-43	-39	-39	N/A
6/30/2018	7	-39	-41	-41	N/A
3/31/2018	7	-41	-43	-42	N/A
12/31/2017	7	-42	N/A	-44	N/A
9/30/2017	7	-47	N/A	-46	N/A
6/30/2017	7	-50	N/A	-47	N/A
3/31/2017	7	-53	N/A	-49	N/A
12/31/2016	6	-53	N/A	-48	N/A
9/30/2016	6	-50	N/A	-49	N/A
6/30/2016	5	-47	N/A	-48	N/A
3/31/2016	4	-44	N/A	-49	N/A
12/31/2015	4	-42	N/A	-47	N/A
9/30/2015	3	-41	N/A	-42	N/A
6/30/2015	3	-38	N/A	-42	N/A
3/31/2015	3	-39	N/A	-36	N/A
12/31/2014	2	-39	N/A	-37	N/A
12/31/2013	0	-80	N/A	-34	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SCIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SCIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SCIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SCIBDie Einnahmen des Unternehmens (40% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.9% pro Jahr).

Hohe Wachstumseinnahmen: SCIBDie Einnahmen des Unternehmens (40% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SCIB in 3 Jahren voraussichtlich hoch sein wird

SciBase Holding Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to kr0.22 loss, revenue downgraded

Forecast to breakeven in 2026

Price target decreased by 13% to kr1.68

Consensus EPS estimates upgraded to kr0.27 loss

Consensus revenue estimates fall by 11%

Price target decreased by 39% to kr4.30

Recent updates

SciBase Holding AB (publ) Appoints Leda Beaty as Head of US Commercial Operations

Consensus EPS estimates upgraded to kr0.22 loss, revenue downgraded

New minor risk - Profitability

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

New major risk - Shareholder dilution

Scibase Announces the Launch of Ebarrier Score, the First Ai-Driven Skin Barrier Assessment Tool for Research and Cosmetic Testing

New minor risk - Shareholder dilution

Price target decreased by 13% to kr1.68

SciBase Holding AB (publ) has completed a Composite Units Offering.

Consensus EPS estimates upgraded to kr0.27 loss

Consensus revenue estimates fall by 11%

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 39% to kr4.30

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

SciBase Holding AB (publ) to Report Fiscal Year 2023 Results on Feb 21, 2024

SciBase Holding AB (publ) to Report Q1, 2024 Results on May 09, 2024

SciBase Holding AB (publ), Annual General Meeting, May 17, 2024

SciBase Holding AB (publ) Appoints Nomination Committee

New major risk - Market cap size

SciBase Holding AB Announces the Publication of A Collaborative Scientific Project with the Swiss Institute of Allergy and Asthma Research in Davos, Switzerland

Chairman & Interim CEO recently bought kr534k worth of stock

Scibase Appoints Pia Renaudin as Chief Executive Officer

Consensus EPS estimates fall by 33%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

SciBase Holding AB (publ) Announces Executive Changes

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to kr0.30 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

SciBase Holding AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

Price target decreased to kr11.00

SciBase Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

SciBase Holding AB (publ) Announces New Study Shows Nevisense Significantly Improves US Clinician's Decision-Making Beyond Dermoscopy

SciBase Holding AB (publ), Annual General Meeting, May 18, 2023

Is SciBase Holding (STO:SCIB) In A Good Position To Deliver On Growth Plans?

SciBase Holding AB Announces Nevisense Detects Skin Barrier Damage in Mice Caused by Household Detergents

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

SciBase Holding AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

SciBase Holding AB (publ) Announces US Study Shows That EIS and Nevisense Significantly Improves Clinicians' Diagnostic Accuracy

Will SciBase Holding (STO:SCIB) Spend Its Cash Wisely?

SciBase Holding AB (publ) Study Shows Clinical Benefit of Nevisense

Full year 2021 earnings released: kr0.67 loss per share (vs kr1.12 loss in FY 2020)

CEO & President recently bought kr76k worth of stock

Independent Chairman recently bought kr504k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Financial Officer recently bought kr111k worth of stock

Third quarter 2021 earnings released: kr0.13 loss per share (vs kr0.20 loss in 3Q 2020)

We're Hopeful That SciBase Holding (STO:SCIB) Will Use Its Cash Wisely

Second quarter 2021 earnings released: kr0.19 loss per share (vs kr0.38 loss in 2Q 2020)

SciBase Holding AB (publ) announced that it has received SEK 71.214109 million in funding from Van Herk Investments B.V., Ostvast Capital Management Limited, and other investors

First quarter 2021 earnings released: kr0.15 loss per share (vs kr0.54 loss in 1Q 2020)

Scibase Receives Important European MDR Certification

SciBase Holding AB (publ) Submits First Reimbursement Application to CMS in Florida

Is SciBase Holding (STO:SCIB) In A Good Position To Deliver On Growth Plans?

David Melin Resigns as Head of Product Development of SciBase AB

Full year 2020 earnings released: kr1.12 loss per share (vs kr2.38 loss in FY 2019)

Revenue beats expectations

SciBase Holding AB (publ) to Report Q3, 2021 Results on Nov 11, 2021

Calculating The Intrinsic Value Of SciBase Holding AB (publ) (STO:SCIB)

SciBase Holding AB (publ) Announces New Study Published Validating Further Nevisense Indication, Non-Melanoma Skin Cancer

New 90-day high: kr4.85

Third quarter 2020 earnings released: kr0.20 loss per share

SciBase Holding AB (publ) to Report Fiscal Year 2020 Results on Feb 19, 2021

Scibase Holding AB (Publ) Announces Positive Step for US Reimbursement of Nevisense

SciBase Holding Releases Next Generation Platform, Nevisense Go

New 90-day high - kr4.14

Earnings released

Gewinn- und Umsatzwachstumsprognosen